Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Completed 3Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Breast Neoplasms 4354Neoplasms 3055Prostatic Neoplasms 1904Colorectal Neoplasms 1738Lung Neoplasms 1555Carcinoma, Non-Small-Cell Lung 1270Pancreatic Neoplasms 981Multiple Myeloma 951Leukemia, Myeloid, Acute 951Lymphoma 912Head and Neck Neoplasms 894Leukemia 852Precursor Cell Lymphoblastic Leukemia-Lymphoma 833Neoplasm Metastasis 793Colonic Neoplasms 785Carcinoma, Hepatocellular 762Ovarian Neoplasms 757Melanoma 752Stomach Neoplasms 740Rectal Neoplasms 701Brain Neoplasms 696Lymphoma, Non-Hodgkin 663Leukemia, Lymphocytic, Chronic, B-Cell 618Uterine Cervical Neoplasms 607Lymphoma, Follicular 559Glioblastoma 541Recurrence 539Hodgkin Disease 532Esophageal Neoplasms 527Myelodysplastic Syndromes 508

Interventions

Imatinib Mesylate 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Dasatinib 1Cytarabine 1Cladribine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × OTHER × Hypereosinophilic Syndrome × Clear all
NCT00255346 2025-12-30

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

M.D. Anderson Cancer Center

Phase 2 Completed
68 enrolled 13 charts
MyeloidOther hematologic neoplasm

Leukemia, Mastocytosis, Myelodysplastic Syndromes, Polycythemia Vera, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Primary Myelofibrosis

NCT00038675 2022-01-04

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate

M.D. Anderson Cancer Center

Phase NA Completed
125 enrolled 9 charts
MyeloidOther hematologic neoplasm

Leukemia, Mastocytosis, Polycythemia Vera, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome

NCT00483067 2012-08-02

2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)

M.D. Anderson Cancer Center

Phase 2 Completed
13 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Hypereosinophilic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡